Published : 01 Mar 2016

---

A New York based plant biotech company has appointed Aagami to find licensing partners for their IP protected smoking cessation aid products.The client is poised to disrupt and penetrate the stale multi-billion dollar smoking cessation market with genetic engineering of the tobacco plant to decrease nicotine and other nicotinic alkaloids.

One of their products is the first and only smoking cessation product in the form of a combustible cigarette. In the US, the Phase 3 the product is going through the FDA-approval process as a prescription smoking cessation aid.

Aagami focus would be finding partnerships with Pharma, Consumer Health and Tobacco companies. Aagami also plans to bring the client to India for some high level discussions and possible deal closures around July 2016.

With this assignment, Aagami is glad to contribute in the noble cause of helping reduce the harm caused by smoking.